Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration to discover and develop a new class of oral drugs that selectively destroy troublesome RNA molecules.
Amgen and the biotech startup Arrakis Therapeutics announced a research collaboration to discover and develop a new class of oral drugs that selectively destroy troublesome RNA molecules.
Copyright © 2026 Biotech Networks, LLC